Company
Chiesi Farmaceutici
Chiesi Farmaceutici has 61 drugs tracked on RxWires: 5 post-market, 25 in Phase 3, 2 in Phase 2/3, 14 in Phase 2, 4 in Phase 1/2, 11 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Atimos® | Post-Market | Pulmonary Disease, Chronic Obstructive |
| Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg | Post-Market | COPD |
| Formoterol | Post-Market | Asthma |
| tobramycin inhalation | Post-Market | Ventilator Associated Pneumonia (VAP) |
| Cangrelor | Post-Market | ST Segment Elevation Myocardial Infarction |
| Pegunigalsidase alfa | Phase 3 | Fabry Disease |
| Lamazym | Phase 3 | Alpha-Mannosidosis |
| Foster 100/6µg NEXThaler | Phase 3 | Asthma |
| Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI | Phase 3 | Asthma |
| amlodipine 10 mg | Phase 3 | Hypertension |
| Beclomethasone Dipropionate/Formoterol Fumarate | Phase 3 | Asthma |
| Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium | Phase 3 | Chronic Obstructive Pulmonary Disease |
| CHF 5993 200/6/12.5 µg | Phase 3 | Asthma |
| CHF5993 100/6/12.5 μg pMDI HFA-152a | Phase 3 | Asthma |
| CHF5993 200/6/12.5 μg pMDI HFA-152a | Phase 3 | Asthma |
| CHF 5993 100/6/12.5 µg | Phase 3 | COPD (Chronic Obstructive Pulmonary Disease) |
| Experimental: Participant Group CHF 5993 pMDI HFA-152a | Phase 3 | Asthma |
| beclomethasone/salbutamol combination | Phase 3 | Asthma |
| beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml | Phase 3 | Croup |
| tobramycin | Phase 3 | Cystic Fibrosis |
| Salbutamol | Phase 3 | Asthma |
| CHF 1535 | Phase 3 | Asthma |
| beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days | Phase 3 | Acute Rhinosinusitis |
| disodium clodronate 200 mg/4 ml with 1% lidocaine | Phase 3 | Postmenopausal Osteoporosis |
| PRX-102 (pegunigalsidase alfa) | Phase 3 | Fabry Disease |
| BDP/Formoterol Next DPI | Phase 3 | Asthma |
| Beclometasone/Formoterol/Glycopyrrolate | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) |
| Glycopyrronium Bromide | Phase 3 | COPD |
| Metreleptin | Phase 3 | Familial Partial Lipodystrophy |
| Inuvair | Phase 3 | Chronic Obstructive Pulmonary Disease |
| PRX-102 1 mg/kg every two weeks | Phase 2/3 | Fabry Disease |
| recombinant human porphobilinogen deaminase (Porphozym) | Phase 2/3 | Acute Intermittent Porphyria |
| CHF1535 NEXThaler | Phase 2 | Asthma |
| BDP/Formoterol | Phase 2 | Asthma |
| Velmanase Alfa (e.g. Lamazym) | Phase 2 | Alpha-Mannosidosis |
| CHF 5259 12.5 µg + Qvar | Phase 2 | Asthma |
| CHF5993 pMDI with HFA-152a | Phase 2 | Asthma |
| CHF6563 | Phase 2 | Neonatal Opioid Withdrawal Syndrome |
| CHF 1535 35/4µg NEXThaler® | Phase 2 | Asthma |
| CHF 5074 1x | Phase 2 | Alzheimer's Disease |
| CHF5633 | Phase 2 | Respiratory Distress Syndrome, Newborn |
| Experimental: CHF6001 3200 μg | Phase 2 | Uncontrolled Asthma |
| Glycopyrrolate | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| CHF5259 or Placebo administration | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) |
| Clenil® Modulite® via AeroChamber Plus™ | Phase 2 | Asthma |
| CHF10067 | Phase 2 | Idiopathic Pulmonary Fibrosis |
| CHF6366 | Phase 1/2 | Asthma |
| CHF6333 | Phase 1/2 | Bronchiectasis |
| Buprenorphine | Phase 1/2 | Neonatal Abstinence Syndrome |
| Meropenem | Phase 1/2 | Meningitis |
| CHF6001 dry powder inhaler (DPI) | Phase 1 | Chronic Obstructive Pulmonary Disease (COPD) |
| Treatment A | Phase 1 | Asthma |
| Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI | Phase 1 | Asthma |
| CHF6001 | Phase 1 | Chronic Obstructive Pulmonary Disease (COPD) |
| CHF6001 DPI | Phase 1 | Chronic Obstructive Pulmonary Disease |
| CHF10073 low dose | Phase 1 | Idiopathic Pulmonary Fibrosis |
| Dabigatran Etexilate | Phase 1 | Healthy Male Volunteers |
| CHF10067 starting dose -- 1000mg (Cohort A) | Phase 1 | Idiopathic Pulmonary Fibrosis |
| CHF 4226 pMDI | Phase 1 | Chronic Obstructive Pulmonary Disease |
| CHF10196 | Phase 1 | |
| CHF10136 | Phase 1 | Asthma |
Latest
No recent events.
Follow Chiesi Farmaceutici on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.